Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Deals

I‑Mab Announces Global Transformation, NovaBridge Rebranding, and $37 M Acquisition of VIS‑101

Fineline Cube Oct 17, 2025

I‑MAB Biopharma (NASDAQ: IMAB), a public company under the CBC Group, today revealed a strategic...

Company Drug

CStone’s Sugemalimab Receives Positive EMA Opinion for Stage III NSCLC

Fineline Cube Oct 17, 2025

CStone Pharmaceuticals (HKG: 2616) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal...

Company Deals

Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia

Fineline Cube Oct 17, 2025

Viatris Inc. (NASDAQ: VTRS) today announced the completion of its acquisition of Aculys Pharma, gaining...

Company Deals

Gan & Lee Pharma, Fiocruz Sign MoU to Advance GZR4 and GZR102 Insulin Candidates

Fineline Cube Oct 17, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) announced today that it has signed a Memorandum of...

Company Deals

Hansoh Pharma Grants Roche Exclusive Global Rights to CDH17‑Targeting ADC HS‑20110

Fineline Cube Oct 17, 2025

Hansoh Pharmaceutical Group (HKG: 3692) today announced a licensing agreement with Roche (SWX: ROG, OTCMKTS:...

Company Drug

Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase II/III Trial

Fineline Cube Oct 17, 2025

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today announced that the U.S. Food...

Company

AstraZeneca China Integrates Symbicort and Breztri Sales Teams in New Organizational Shake‑Up

Fineline Cube Oct 17, 2025

AstraZeneca (AZ; NASDAQ: AZN) announced a strategic re‑alignment of its respiratory inhalation portfolio in China, consolidating...

Company Deals

Leads Biolabs, Dianthus Therapeutics Announce Global Partnership for LBL‑047 Bispecific Fusion Protein

Fineline Cube Oct 17, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) today announced an exclusive global partnership with Dianthus Therapeutics...

Company Deals

NeuroGen Pharma Secures Exclusive Rights to Brexpiprazole Orally Disintegrating Film from Bocimed

Fineline Cube Oct 16, 2025

China‑based NeuroGen Pharma and Bocimed announced today that they have entered into an exclusive product‑transfer...

Company Drug

Chia Tai Tianqing Secures NMPA Approval for Phase III Trial of TQB2868 + Anlotinib in First‑Line mPDAC Therapy

Fineline Cube Oct 16, 2025

Chia Tai Tianqing, a wholly‑owned subsidiary of Sino Biopharmaceutical (HKG: 1177), announced today that the...

Company Drug

Lepu Biopharma Enrolls First Patient in Phase II Trial of MRG006A, the World’s First GPC3‑Targeting ADC

Fineline Cube Oct 16, 2025

Lepu Biopharma Co., Ltd. (HKG: 2157) announced today that it has successfully enrolled the first...

Company Deals

Jacobio Pharmaceuticals Secures 80% Equity Investment in Jacoray from Oceanpine Capital

Fineline Cube Oct 16, 2025

Jacobio Pharmaceuticals (HKG: 1167) today announced a capital‑increase and equity‑transfer agreement that will see Shanxi...

Policy / Regulatory

Zhejiang Authority Imposes Administrative Penalties on Dahongying Pharma for Substandard Fluorouracil Injection

Fineline Cube Oct 16, 2025

The Zhejiang Provincial Medical Products Administration announced that Ningbo Dahongying Pharmaceutical Co., Ltd. has been...

Company Drug

HELP Therapeutics Secures NMPA Approval for HiCM388, China’s First Cell‑Based Therapy for STEMI

Fineline Cube Oct 16, 2025

HELP Therapeutics Corp., a pioneer in cell‑based therapeutics, announced that the National Medical Products Administration...

Company

Abbott Reports Q3 2025 Revenue of $11.369 B, Up 6.9% YoY – Strong Growth Across Nutrition & Devices Segments

Fineline Cube Oct 16, 2025

Abbott Laboratories (NYSE: ABT) today released its financial results for the quarter ended September 30, 2025. For...

Company Deals

Haihe Biopharma Grants Taiho Pharmaceutical Exclusive License for Risovalisib in Japan

Fineline Cube Oct 16, 2025

China‑based Haihe Biopharma Co., Ltd. (the “Licensor”) announced today that it has entered into an...

Company Deals

Genesis Healthcare & MGI Sign Strategic MOU to Accelerate Precision Medicine in Japan

Fineline Cube Oct 16, 2025

Genesis Healthcare, a leading Japanese genetic‑testing provider, today announced the signing of a Memorandum of...

Company Deals

Nuance Pharma Partners with Stallergenes Greer to Launch Actair in China

Fineline Cube Oct 15, 2025

Nuance Pharma, an innovation-focused biopharmaceutical company, and Stallergenes Greer, a global leader in the allergy...

Policy / Regulatory

Pfizer CEO Bourla Highlights Benefits of China Biotech Collaborations at NY Gala

Fineline Cube Oct 15, 2025

Albert Bourla, CEO of Pfizer Inc. (NYSE: PFE), highlighted the benefits of collaborations between multinational...

Company Deals

Uni-Bio Science Partners with Sinovac to Expand Teriparatide Injection Globally

Fineline Cube Oct 15, 2025

Uni-Bio Science Group Limited (HKG: 0690), a China-based company, announced on September 12, 2025, that...

Posts pagination

1 … 146 147 148 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.